Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have received an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $22.75.
A number of analysts have recently weighed in on PRTK shares. Zacks Investment Research cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. HC Wainwright cut their price target on Paratek Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, BTIG Research set a $36.00 price objective on Paratek Pharmaceuticals and gave the company a “sell” rating in a research report on Friday, November 1st.
Shares of Paratek Pharmaceuticals stock traded up $0.17 during trading hours on Monday, reaching $3.27. The company’s stock had a trading volume of 531,815 shares, compared to its average volume of 491,786. Paratek Pharmaceuticals has a one year low of $2.66 and a one year high of $7.39. The company’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $3.71. The company has a current ratio of 9.80, a quick ratio of 9.45 and a debt-to-equity ratio of 14.48.
In related news, insider Randall B. Brenner sold 7,674 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total value of $30,542.52. Following the completion of the transaction, the insider now directly owns 91,338 shares of the company’s stock, valued at approximately $363,525.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Evan Loh sold 16,265 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total value of $64,734.70. Following the completion of the transaction, the chief executive officer now directly owns 413,935 shares of the company’s stock, valued at $1,647,461.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,079 shares of company stock worth $145,472. Corporate insiders own 7.70% of the company’s stock.
A number of institutional investors have recently made changes to their positions in PRTK. Bank of Montreal Can boosted its position in Paratek Pharmaceuticals by 503.1% during the 2nd quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 6,520 shares during the period. Alambic Investment Management L.P. bought a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at about $82,000. A.R.T. Advisors LLC bought a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at about $121,000. Susquehanna International Group LLP lifted its holdings in Paratek Pharmaceuticals by 33.0% in the second quarter. Susquehanna International Group LLP now owns 32,060 shares of the specialty pharmaceutical company’s stock worth $128,000 after purchasing an additional 7,960 shares during the period. Finally, Citadel Advisors LLC lifted its holdings in Paratek Pharmaceuticals by 7.2% in the second quarter. Citadel Advisors LLC now owns 114,250 shares of the specialty pharmaceutical company’s stock worth $456,000 after purchasing an additional 7,639 shares during the period. 67.64% of the stock is currently owned by hedge funds and other institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Read More: S&P/TSX Index
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.